Insights
webinar
The Shift Toward US Pharmaceutical Manufacturing
The COVID-19 pandemic brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. In this webinar we will discuss drivers to consider i...
webinar
Efficient Biologics Production
In this GEN webinar, our guest speakers, Dr. Tyler Jones and Senior Research Scientist Dylan Ting will discuss strategies to leverage efficiency from cell line development to clinical manufacturing of biologics. Moreover, we will hear how proprietary...
webinar
FDA's Quality Management Maturity Program – Why should CDMOs adhere to the new CDER's Rati
The objective of this webinar is to explore the QMM program and its benefits, including the rating system currently being developed by the FDA’s Center for Drug Evaluation and Research (CDER) to incentivize drug manufacturers to achieve QMM. We wi...
webinar
Ensuring Patient Safety: Decoding FDA’s Rating System for CDMOs
To optimize manufacturing process performance and product quality, enhance supply chain reliability, and foster proactive continual improvement, the FDA’s Center for Drug Evaluation and Research (CDER) has established a program to promote quality m...
white paper
Resource savings through effective:
Global Trade Compliance in Drug Development
The increasing global trade of pharmaceutical products underscores the need for (bio)pharmaceutical companies to be well-versed in international trade requirements. This white paper explores the impact of factors like the COVID-19 pandemic on global...
white paper
FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?
Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...
article
Outsourcing Your Parenteral Manufacturing – Choosing the Optimal CDMO
When a drug substance requires a parenteral formulation to administer it, there are key factors to consider when choosing the ideal CDMO partner.
article
The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers
For many who are new to drug development, the greatest challenge is not necessarily discovering a blockbuster molecule—it’s finding a team capable of carrying that molecule through the complexities that lie between the research lab and the patien...
webinar
Casual Nexus – Episode Four: Strategies for HPAPI Containment to Enable Rapid Development and Production
Presented by Brian Haney, Ph.D., Director of Technical Operations, Curia Iain MacGilp, Ph.D., Director, GMP Production, Curia Listen in as our experts discuss: The basics of handling HPAPI's safely in GMP production settings The trad...
webinar
Casual Nexus – Episode Three: Sterile Drug Product Manufacturing During a Global Pandemic
Presenters: Ankit Agrawal, Senior Director, Commercial Strategy, Curia Anish Parikh, Vice President, Drug Product Sales & Marketing, Curia Listen in as our experts discuss: The shortage of sterile manufacturing capacity within CDMOs given...
webinar
Casual Nexus – Episode One: Formulation Development and Clinical Supply of Aseptic Liposomal
Presenters: Iain MacGilp, Ph.D., Director, GMP Production, Curia Amber McFarlane, Head of Formulation Development, Curia Listen in as our experts discuss: The importance of an integrated formulation development and clinical supply function th...
article
Curia Signs on to Participate in Diversity Lab’s Mansfield Certification Program
As part of our deep commitment to diversity and inclusion in the workplace, Curia is very proud to be participating in the two-year Mansfield Rule: Legal Department Edition (MRLD) initiative.